7.46
-0.41 (-5.21%)
| Previous Close | 7.87 |
| Open | 7.95 |
| Volume | 1,205,655 |
| Avg. Volume (3M) | 2,451,783 |
| Market Cap | 544,515,840 |
| Price / Sales | 1.32 |
| Price / Book | 0.860 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | -10.92% |
| Operating Margin (TTM) | 37.82% |
| Diluted EPS (TTM) | -0.660 |
| Quarterly Revenue Growth (YOY) | 646.20% |
| Total Debt/Equity (MRQ) | 1.59% |
| Current Ratio (MRQ) | 4.58 |
| Operating Cash Flow (TTM) | -250.70 M |
| Levered Free Cash Flow (TTM) | -2.69 M |
| Return on Assets (TTM) | -5.39% |
| Return on Equity (TTM) | -7.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arvinas, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.75 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.74% |
| % Held by Institutions | 91.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 31 Mar 2025 | 1,585,721 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (HC Wainwright & Co., 221.72%) | Buy |
| Median | 11.00 (47.45%) | |
| Low | 8.00 (Goldman Sachs, 7.24%) | Hold |
| Average | 13.73 (84.05%) | |
| Total | 7 Buy, 6 Hold | |
| Avg. Price @ Call | 7.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 02 Jun 2025 | 9.00 (20.64%) | Hold | 7.33 |
| UBS | 15 May 2025 | 21.00 (181.50%) | Buy | 6.26 |
| Morgan Stanley | 09 May 2025 | 11.00 (47.45%) | Hold | 6.61 |
| BMO Capital | 05 May 2025 | 10.00 (34.05%) | Buy | 7.63 |
| Citigroup | 05 May 2025 | 9.50 (27.35%) | Hold | 7.63 |
| Truist Securities | 05 May 2025 | 11.00 (47.45%) | Hold | 7.63 |
| Barclays | 02 May 2025 | 16.00 (114.48%) | Buy | 7.72 |
| Goldman Sachs | 02 May 2025 | 8.00 (7.24%) | Hold | 7.72 |
| 17 Apr 2025 | 12.00 (60.86%) | Hold | 8.60 | |
| Guggenheim | 02 May 2025 | 16.00 (114.48%) | Buy | 7.72 |
| HC Wainwright & Co. | 02 May 2025 | 24.00 (221.72%) | Buy | 7.72 |
| Jefferies | 02 May 2025 | 10.00 (34.05%) | Hold | 7.72 |
| Piper Sandler | 02 May 2025 | 14.00 (87.67%) | Buy | 7.72 |
| Wells Fargo | 02 May 2025 | 19.00 (154.69%) | Buy | 7.72 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |